RAD51 and neoplasm: Notably, inhibitors targeting pathways such as mTOR, PI3K, and the cell cycle/DNA replication machinery may act downstream of TONSL, TIMELESS, RFC3, and RAD51. These pathways have been widely recognized for their crucial roles in tumor progression (41–43).